255 related articles for article (PubMed ID: 33747510)
21. Spotlight on omalizumab in allergic asthma.
Bang LM; Plosker GL
BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
23. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
24. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy.
Jensen RK; Jabs F; Miehe M; Mølgaard B; Pfützner W; Möbs C; Spillner E; Andersen GR
Allergy; 2020 Aug; 75(8):1956-1965. PubMed ID: 32037590
[TBL] [Abstract][Full Text] [Related]
25. Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy.
Storms W
Am J Respir Med; 2002; 1(5):361-8. PubMed ID: 14720038
[TBL] [Abstract][Full Text] [Related]
26. Structural and Physical Basis for Anti-IgE Therapy.
Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
[TBL] [Abstract][Full Text] [Related]
27. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
28. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
D'Amato G; Bucchioni E; Oldani V; Canonica W
Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
Sheldon E; Schwickart M; Li J; Kim K; Crouch S; Parveen S; Kell C; Birrell C
Adv Ther; 2016 Feb; 33(2):225-51. PubMed ID: 26843086
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
Félix Toledo R; Negro Alvarez JM; Miralles López JC
Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
[TBL] [Abstract][Full Text] [Related]
32. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES; Dobson CL; Käck H; Wang B; Sims DA; Lloyd CO; England E; Rees DG; Guo H; Karagiannis SN; O'Brien S; Persdotter S; Ekdahl H; Butler R; Keyes F; Oakley S; Carlsson M; Briend E; Wilkinson T; Anderson IK; Monk PD; von Wachenfeldt K; Eriksson PO; Gould HJ; Vaughan TJ; May RD
MAbs; 2014; 6(3):756-64. PubMed ID: 24583620
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
34. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
Lowe PJ; Renard D
Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
[TBL] [Abstract][Full Text] [Related]
35. Effects of omalizumab on markers of inflammation in patients with allergic asthma.
Holgate S; Smith N; Massanari M; Jimenez P
Allergy; 2009 Dec; 64(12):1728-36. PubMed ID: 19839977
[TBL] [Abstract][Full Text] [Related]
36. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma.
Ruffin CG; Busch BE
Am J Health Syst Pharm; 2004 Jul; 61(14):1449-59. PubMed ID: 15332692
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
Massanari M; Kianifard F; Zeldin RK; Geba GP
Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
[TBL] [Abstract][Full Text] [Related]
39. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
Berger W; Gupta N; McAlary M; Fowler-Taylor A
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
